Moving on from 2013 to 2020 European LeukemiaNet recommendations for treating chronic myeloid leukemia: what has changed over the 7 years?

A Novel System for Semiautomatic Sample Processing in Chronic Myeloid Leukaemia: Increasing Throughput without Impacting on Molecular Monitoring at Time of SARS-CoV-2 Pandemic

“…Upon TKI therapy initiation, Q-PCR should be repeated every 3 months until MR 3 is achieved, and then continued every 3-6 months [49][50][51]. Moreover, a group of CML patients with persistent deep molecular response after TKIs discontinuation (a condition defined as TFR) should be monitored more strictly to ensure a timely recognition of relapse [31,41,52].…”

“…However, this interval may vary according to the clinical context. Mainly, CML patients with TFR require monthly Q-PCR determination during the first six months after drug discontinuation, in order to determine that the desired level of molecular response is maintained over the time [19,[41][42][43].…”

Asciminib in chronic myeloid leukemia: many questions still remain to be answered

“…Or do they prefer to continue asciminib in patients who achieve and maintain optimal responses regardless of transplant eligibility? Asciminib is a potential treatment approach as stated in the most recent European LeukemiaNet recommendations 3,10 . It previously showed promising results in heavily pretreated patients with acceptable toxicity profile 6,7 , and in line with these findings, Garcia-Gutiérrez et al 8 .…”

Bosutinib – related pleural effusion in patients with chronic myeloid leukemia

“…Tyrosine kinase inhibitors (TKIs) are the mainstay of the current management of chronic myeloid leukemia (CML) [1]. With the introduction of imatinib, many CML patients in chronic phase (CML-CP) were able to achieve and maintain durable responses, however, approximately 40% of these patients switch to alternative TKIs due to intolerance and/or failure [2].…”